News
Media
Conferences
Events
Publication
CME/CE
Resources
Editorial Advisory Board
Partners
Subscribe

Opinion|Videos|November 15, 2024

Roflumilast: Mechanism, and Use for Proactive AD Management

Author(s)Lisa Swanson, MD, FAAD, Benjamin Lockshin, MD, FAAD

Key Takeaways

PDE4 inhibitors vary in selectivity, binding affinity, and pharmacokinetics, affecting therapeutic outcomes and adverse effects.
Differences in isoform selectivity and tissue distribution influence efficacy and safety profiles of PDE4 inhibitors.
Understanding these distinctions is crucial for optimizing treatment strategies and minimizing side effects.

SHOW MORE

Panelists discuss common misconceptions about the mechanism of action of PDE4 inhibitors in clinical practice, emphasizing that not all PDE4 inhibitors are created equal and how these differences can significantly impact their efficacy and safety profiles.

Episodes in this series

EP. 1 Evolution of Topical Treatment for AD

EP. 1 Evolution of Topical Treatment for AD

EP. 2 PDE4 Inhibitor Roflumilast for AD

EP. 2 PDE4 Inhibitor Roflumilast for AD

EP. 3 Comparing the Efficacy of Roflumilast and Crisaborole

EP. 3 Comparing the Efficacy of Roflumilast and Crisaborole

EP. 4 Roflumilast: Mechanism, and Use for Proactive AD Management

EP. 4 Roflumilast: Mechanism, and Use for Proactive AD Management

EP. 5 Considerations for Using Roflumilast in the Pediatric Population, and for Skin of Color

EP. 5 Considerations for Using Roflumilast in the Pediatric Population, and for Skin of Color

EP. 6 Patient Education and Novel Topical Therapies for AD

EP. 6 Patient Education and Novel Topical Therapies for AD

EP. 7 Pediatric and Adult AD Cases Illuminate Benefits of Topical PDE4 Inhibitors

EP. 7 Pediatric and Adult AD Cases Illuminate Benefits of Topical PDE4 Inhibitors

What are some common misconceptions about the mechanism of PDE4 inhibitors that you encounter in clinical practice?
1. Please explain why all PDE4 inhibitors are not created equal. How might these differences impact efficacy and safety profile?

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Latest CME

Dermalorian™ Webinar: Shedding Light on Patient-Reported Outcomes to Assess Disease Severity in Patients With Atopic Dermatitis

Dermalorian™ Webinar: Shedding Light on Patient-Reported Outcomes to Assess Disease Severity in Patients With Atopic Dermatitis

Joseph Gorelick, MSN, FNP-C

Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?

Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?

Brad P. Glick, DO, MPH, FAAD

Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management

Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management

Hilary Baldwin; Neal Bhatia, MD

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Tina Bhutani, MD

Revolutionizing Atopic Dermatitis (RAD) Conference 2026

In-Person Event

Revolutionizing Atopic Dermatitis (RAD) Conference 2026

June 17-19, 2026

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Diego Ruiz Dasilva, MD, FAAD; Brad Glick, DO, MPH. FAAD; Peter Lio, MD

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Brittany Weber MD, PhD, FACC, FAHA; Lourdes M. Perez-Chada MD, MMSc

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Andrew Alexis, MD, MPH; Leon Kircik, MD

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Johann Gudjonsson, MD, PhD; Christopher Bunick, MD, PhD

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Andrew F. Alexis, MD, MPH; Chesahna Kindred, MD, MBA, FAAD

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Douglas DiRuggiero, DMSc, MHS, PA-C; Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Jerry Bagel, MD, MS

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hadar Lev-Tov, MD; Martina Porter, MD

Trending on Dermatology Times

Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results

Reviewing Type 2 Inflammation Through a Different Lens

Derm Dispatch: What 'Free to Be Me' Means to Tori Spelling and Stella McDermott

Alpha-9 Begins First-in-Human Trial of MC1R-Targeted Radiotherapeutic

Dermatology Conferences and Meetings Calendar: December 2025

© 2025 MJH Life Sciences^®

All rights reserved.